Olivier Le Rouzic

Olivier Le Rouzic

Auto-generated profile, based on publicly available information

Olivier Le Rouzic

Univ. Lille, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2017 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
OROlivier Le Rouzic
Olivier Le Rouzic
MPMuriel Pichavant
Muriel Pichavant
EFEmilie Frealle
Emilie Frealle
AGAntoine Guillon
Antoine Guillon
MSMustapha SI-TAHAR
Mustapha SI-TAHAR
PGPhilippe Gosset
Philippe Gosset
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways caused mainly by cigarette smoke exposure. COPD progression is marked by exacerbations of the disease, often associated with infections. Recent data show the involvement in COPD pathophysiology of interleukin (IL)-17 and IL-22, two cytokines that are important in the control of lung inflammation and infection. During the initiation and progression of the disease, increased IL-17 secretion causes neutrophil recruitment, leading to chronic inflammation, airways obstruction and emphysema. In the established phase of COPD, a defective IL-22 response facilitates pathogen-associated infections and disease exacerbations. Altered production of these cytokines involves a complex network of immune cells and dysfunction of antigen-presenting cells. In this review, we describe current knowledge on the involvement of IL-17 and IL-22 in COPD pathophysiology at steady state and during exacerbations, and discuss implications for COPD management and future therapeutic approaches.

1 November 2013 in Chest
Verified
Journal Article
Closed access
PDF file
BWBenoit Wallaert
Benoit Wallaert
EMEmmanuel Monge
Emmanuel Monge
OROlivier Le Rouzic
Olivier Le Rouzic
LWLidwine Wémeau-Stervinou
Lidwine Wémeau-Stervinou
JSJulia Salleron
Julia Salleron
JGJean-Marie Grosbois
Jean-Marie Grosbois

1 May 2018 in Chest
Verified
Journal Article
Closed access
OROlivier Le Rouzic
Olivier Le Rouzic
NRNicolas Roche
Nicolas Roche
ACAlexis B. Cortot
Alexis B. Cortot
ITIsabelle Tillie-Leblond
Isabelle Tillie-Leblond
FMFrédéric Masure
Frédéric Masure
BHBruno Housset
Bruno Housset

1 May 2014 in Mucosal Immunology
Verified
Journal Article
Open access
MPMuriel Pichavant
Muriel Pichavant
GRGaëlle Rémy
Gaëlle Rémy
SBS Bekaert
S Bekaert
ORO Le Rouzic
O Le Rouzic
GKG Kervoaze
G Kervoaze
PGP Gosset
P Gosset
Chronic obstructive pulmonary disease (COPD) is a major clinical challenge mostly due to cigarette smoke (CS) exposure. Invariant natural killer T (iNKT) cells are potent immunoregulatory cells that have a crucial role in inflammation. In the current study, we investigate the role of iNKT cells in COPD pathogenesis. The frequency of activated NKT cells was found to be increased in peripheral blood of COPD patients relative to controls. In mice chronically exposed to CS, activated iNKT cells accumulated in the lungs and strongly contributed to the pathogenesis. The detrimental role of iNKT cells was confirmed in an acute model of oxidative stress, an effect that depended on interleukin (IL)-17. CS extracts directly activated mouse and human dendritic cells (DC) and airway epithelial cells (AECs) to trigger interferonγ and/or IL-17 production by iNKT cells, an effect ablated by the anti-oxidant N-acetylcystein. In mice, this treatment abrogates iNKT-cell accumulation in the lung and abolished the development of COPD. Together, activation of iNKT cells by oxidative stress in DC and AECs participates in the development of experimental COPD, a finding that might be exploited at a therapeutic level.

1 September 2015 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
BWBenoit Wallaert
Benoit Wallaert
JGJean-Marie Grosbois
Jean-Marie Grosbois
AGAlice Gicquello
Alice Gicquello
CLCarole Langlois
Carole Langlois
OROlivier Le Rouzic
Olivier Le Rouzic
FBFrederic Bart
Frederic Bart
Introduction: Personalized, global pulmonary rehabilitation (PR) management of patients with COPD is effective, regardless of the place in which this rehabilitation is provided. The objective of this retrospective observational study was to study the long-term outcome of exercise capacity and quality of life during management of patients with COPD treated by home-based PR. Methods: Home-based PR was administered to 211 patients with COPD (mean age, 62.3±11.1 years; mean forced expiratory volume in 1 second, 41.5%±17.7%). Home-based PR was chosen because of the distance of the patient’s home from the PR center and the patient’s preference. Each patient was individually managed by a team member once a week for 8 weeks with unsupervised continuation of physical exercises on the other days of the week according to an individual action plan. Exercise conditioning, therapeutic patient education, and self-management were included in the PR program. The home assessment comprised evaluation of the patient’s exercise capacity by a 6-minute stepper test, Timed Up and Go test, ten times sit-to-stand test, Hospital Anxiety and Depression score, and quality of life (Visual Simplified Respiratory Questionnaire, VQ11, Maugeri Respiratory Failure 28). Results: No incidents or accidents were observed during the course of home-based PR. The 6-minute stepper test was significantly improved after completion of the program, at 6 months and 12 months, whereas the Timed Up and Go and ten times sit-to-stand test were improved after PR and at 6 months but not at 12 months. Hospital Anxiety and Depression and quality of life scores improved after PR, and this improvement persisted at 6 months and 12 months. Conclusion: Home-based PR for unselected patients with COPD is effective in the short term, and this effectiveness is maintained in the medium term (6 months) and long term (12 months). Home-based PR is an alternative to outpatient management provided all activities, such as exercise conditioning, therapeutic education, and self-management are performed.

1 October 2019 in ERJ Open Research
Verified
Journal Article
Open access
MTMacha Tetart
Macha Tetart
FWFrederic Wallet
Frederic Wallet
MKMaeva Kyheng
Maeva Kyheng
SLSylvie Leroy
Sylvie Leroy
TPThierry Perez
Thierry Perez
APAnne Prevotat
Anne Prevotat
Background: The prevalence ofAchromobacter xylosoxidanslung isolation in cystic fibrosis (CF) patients has increased, but the impact on lung function is controversial. The aim of this study was to evaluate the long-term effects ofA. xylosoxidansisolation on respiratory function of adult patients with CF in the first 3 years after identification ofA. xylosoxidansisolation.Methods: This was a case–control retrospective study performed at a single CF centre in Lille, France. Data for 36 patients with CF who had at least one sputum culture positive forA. xylosoxidans(Ax+) were evaluated and compared with control CF patients uninfected byA. xylosoxidans(Ax−). Respiratory function and exacerbation frequency were evaluated between 1 year prior to and 3 years afterA. xylosoxidansisolation.Results: Compared with theAx− group, theAx+group had a lower forced expiratory volume in 1 s (FEV1) at baseline (median (interquartile range): 55.2% (50.6–59.8%)versus73.8% (67.2–80.4%); p=0.005), a greater decline in FEV1(±se) in the first year afterA. xylosoxidansidentification (−153.6±16.1 mL·year−1versus−63.8±18.5 mL·year−1; p=0.0003), and more exacerbations in the first 3 years afterA. xylosoxidansidentification (9 (7–12)versus7 (5–10); p=0.03).Ax+patients co-colonised withPseudomonas aeruginosa(n=27, 75%) had a greater FEV1decline (p=0.003) and more exacerbations in the year afterA. xylosoxidansidentification (p=0.037) compared with patients colonised withA. xylosoxidansalone. Patients with chronicA. xylosoxidansisolation (n=23, 64%) had more exacerbations than intermittently colonised patients in the 3 years afterA. xylosoxidansidentification (p=0.012).Conclusion: A. xylosoxidansisolation is associated with a decline in respiratory function in patients with CF. ChronicA. xylosoxidansisolation andP. aeruginosaco-isolation may be markers of more severe respiratory disease inAx+ patients.